96 та эркак каламушлар тартибсиз равишда икки гуруҳга бўлинди. Тадқиқотнинг барча курси давомида каламушлар стандарт равишда озиқлантирилди ва тош ҳосил бўлиш индуктори сифатида 0,75% этиленгликоль бўлган ичимлик суви берилди. Буйракларда СаОх депозитлари пайдо бўлгандан сўнг, биринчи гуруҳдаги каламушлар аралашма экстрактини қабул қилишди, иккинчи, яъни назорат гуруҳидаги каламушлар эса плацебо қабул қилишди. Аралашма экстракти кучли диуретик таъсирга (69,1%) эга эканлиги аниқланди. Уролитиаз ингибиторлари ва промоутерларида ўзгаришлар кузатилди: сийдик рН ва и цитрат экскрециясининг ошиши, кальциурия ва оксалуриянинг камайиши. Сийдик йўлларида литогенез фаоллигининг пасайишини бирламчи кўрсаткичдан 70,86%гача АР[CaOx] индиксининг пасайганлиги тасдиқлади. Биз томондан ишлаб чиқилган сийдик хайдовчи фито аралашма табиий воситаларнинг нафақат сийдик хайдовчи, балки сийдик йўлларида литогенез омилларига таъсирини кўрсатди. Юқори диуретик таъсири ҳамда уролитиаз промоутер ва ингибиторларининг балансини нормаллаштириш хусусиятига эга эканлиги ҳисобга олиб, ушбу аралашмани уролитиаз билан оғриган беморларда даволаш мақсадида қўллаш мумкин.
The 96 male rats were randomly divided into two groups. The standard nutrition and drinking water with 0.75% EG as an inducer of stone formation were free for all rats. The first group received an extract from DG; the second group (control) received a placebo. The strong diuretic effect of the extract was found - by 69.1%. A significant change in inhibitors and promoters of urolithiasis was observed: an increase in urine pH and citrate excretion, a decrease in calciuria and oxaluria. The decrease in the activity of lithogenesis was confirmed by a decrease in the AP [CaOx] index by 70.86% from the baseline. The results confirm that diuretic plant has demonstrated the ability of herbal preparations, in addition to the diuretic effect, to influence on factors of urinary lithogenesis. The high diuretic effect in combination with ability of DG to normalise the balance of promoters and inhibitors, allows us to offer it for the management of patients with urolithiasis
| № | Муаллифнинг исми | Лавозими | Ташкилот номи |
|---|---|---|---|
| 1 | Kariyev S.S. | Ташкентский институт усовершенствования врачей |
| № | Ҳавола номи |
|---|---|
| 1 | 1. Khan SR. Animal models of kidney stone for-mation: an analysis. World J Urol. 1997; 15:236–243. 2. Lee YH, Chang LS, Chen MT. Characterization of ethylene glycol induced urolithiasis model in rats. J Urol ROC 1991. 2:518–524. 3. Lee YH, Huang WC, Chiang H. Determinant role of testosterone in the pathogenesis of urolithiasis in rats. J Urol 1992. 147:1134–1138. 4. Lee YH, Tsai JY, Huang JK. Combined use of 30% lactose rich diet and 1% ethylene glycol: a new animal model for study of urolithiasis. J Urol ROC 2000. 11:149–154. 5. Leth PM, Gregersen M. Ethylene glycol poison-ing. Forensic Sci Int 2005. 155: 179–184. 6. Green ML, Hatch M, Freel RW. Ethylene glycol induces hyperoxaluria without metabolic acidosis in rats. Am J Physiol Renal Physiol 2005. 289:F536–F543. 7. Pearle MS, Goldfarb DS, Assimos DG et al. Medical management of kidney stones: AUA guideline. J Urol. 2014. 192(2):316–324 8. Skolarikos A, Straub M, Knoll T et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015. 67(4):750–763 9. Каприн А.Д., Аполихин О.И., Сивков А.В., и др. Анализ уронефрологической заболеваемости и смертности в Российской Федерации за 2003-2013 гг. Экспериментальная и клиническая урология №2 2015, с4-12 10. Talati JJ, Tiselius HG, Albala DM, YE Z. Urolithiasis. Basic Science and Clinical Practice. ISBN: 978-14471-4383 (Print), Springer London, 2012. 11. Park S, Pearle MS. Pathophysiology and management of calcium stones. Urol Clin North Am. 2007; 34:323–334. |